Alder BioPharma Issues Phase 2b Study Data for Eptinezumab: 'Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion'

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!